Asish K Ghosh

5PUBLICATIONS
13CO-AUTHORS
Molecular targetsHaematological tumoursCancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation and matter
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 23, 2026
Aberrant expression of MERTK activates BCR via CD79a in CLL cells: alternative therapeutic strategy for relapsed/refractory CLL.

|Dec 05, 2024
Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy.

Murali K Mamidi, Sutapa Sinha, Mariana T Mendez

|Jun 17, 2024
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.

Sutapa Sinha, Ray Guo, Miles D Del Busso

|May 14, 2022
Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.

Murali K Mamidi, Hasan Mahmud, Guru P Maiti

|May 18, 2021
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis.

Guru P Maiti, Sutapa Sinha, Hasan Mahmud

Pageof 1

Frequent Collaborators

3 joint publications

Neil E Kay

2 joint publications

Guru P Maiti

2 joint publications

Jennifer R Brown

2 joint publications

Sutapa Sinha